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Reimbursement-Based Economics – What Is It and How Can
We Use It to Inform Drug Policy Reform?
Doug Coyle, MA, MSc, PhD; Karen M. Lee, MA; Muhammad Mamdani, MPH, MA, PharmD;
Kelley-Anne Sabarre, MSc; Kylie Tingley, BSc, PhD (cand.)
Background.—In Ontario, approximately $3.8 billion is spent annually on publicly funded drug programs. The annual
growth in Ontario Public Drug Program (OPDP) expenditure has been limited to 1.2% over the course of 3 years. Concur-
rently, the Ontario Drug Policy Research Network (ODPRN) was appointed to conduct drug class review research relating to
formulary modernization within the OPDP. Drug class reviews by ODPRN incorporate a novel methodological technique
called reimbursement-based economics, which focuses on reimbursement strategies and may be particularly relevant for
policy-makers.
Objectives.—To describe the reimbursement-based economics approach.
Methods.—Reimbursement-based economics aims to identify the optimal reimbursement strategy for drug classes by
incorporating a review of economic literature, comprehensive budget impact analyses, and consideration of cost-effectiveness.
This 3-step approach is novel in its focus on the economic impact of alternate reimbursement strategies rather than individual
therapies.
Results.—The methods involved within the reimbursement-based approach are detailed. To facilitate the description,
summary methods and findings from a recent application to formulary modernization with respect to the drug class tryptamine-
based selective serotonin receptor agonists (triptans) used to treat migraine headaches are presented.
Conclusions.—The application of reimbursement-based economics in drug policy reforms allows policy-makers to consider
the cost-effectiveness and budget impact of different reimbursement strategies allowing consideration of the trade-off between
potential cost savings vs increased access to cost-effective treatments.
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In Ontario, approximately $3.8 billion is spent
annually through the Ontario Public Drug Program
(OPDP), which is funded through general taxation
revenues.1 Approximately 20% of Ontarians are eli-
gible to receive drugs through the OPDP – access is
restricted to those over age 65 years, those receiving
welfare, and those receiving home care or living in
long-term care facilities.
Typically, drugs that are publicly funded are
either listed in the Ontario Drug Benefit (ODB)
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Formulary or are part of the Exceptional Access
Program (EAP). Within the ODB Formulary, drugs
can be available as either general benefit (GB) or
limited use (LU). Under GB, drugs are available to all
covered by the OPDP with a prescription completed
by a physician. Under LU, drugs are available to all
covered by the OPDP with a prescription and who
meet specified criteria as assessed by a physician. For
EAP, drugs are available only when patients meet
specified criteria as assessed by a physician and
further evaluated by the OPDP staff.
More than 3200 drug products are currently listed
under the ODB Formulary2 and a further 850 drug
products are available under EAP.3
In 2012, as part of the strategy to eliminate pro-
vincial debt by 2017-2018, the OPDP expenditure
was limited to a spending growth of 1.2% over the
course of 3 years.4 Consequently, the OPDP empha-
sized its commitment to continue to publicly fund
drugs for Ontarians and to identify areas for savings
and efficiencies in the health system.4 Concurrently,
the Ontario Drug Policy Research Network
(ODPRN) was awarded provincial government
funding to conduct research relating to formulary
modernization (a re-evaluation of currently publicly
funded drugs through the review of “current evi-
dence to support clinical benefit, safety, and value for
money”).5 This could help OPDP’s objectives by
identifying areas for savings and efficiencies but also
identify areas in need of improved access to effective
drug therapies. The ODPRN process is a novel, inte-
grated program that includes systematic reviews of
the literature, real-world, population-based analyses
of drug utilization trends and qualitative analyses of
the opinions and perspectives of patients, prescribers,
and dispensers of the drugs. In addition, the drug
class reviews incorporates a novel methodological
technique called reimbursement-based economics,
which is the focus of this article. The ODPRN
approach to evidence-informed formulary modern-
ization is unique worldwide.
The objective of this article is to describe the
constituent components of the reimbursement-based
economics approach. The initial application of the
ODPRN process to the treatment of migraines by
triptans is used to demonstrate how reimbursement-
based economics is being applied to OPDP formulary
modernization initiatives. Given the explicit purpose
of this article is to highlight the approach adopted, the
methods and findings of this analysis are summarized
in this study with greater details provided in the com-
pleted study report.6
CASE STUDY: TRIPTANS FOR THE
MANAGEMENT OF MIGRAINES6
To demonstrate how reimbursement-based eco-
nomics can help facilitate formulary modernization –
the ODPRN drug class review for tryptamine-based
selective serotonin receptor agonists (triptans) used
to treat migraine headaches is presented as a case
study.
Currently, there are 7 triptans available for the
management of migraines in Canada, of which 5
are publicly funded in Ontario and available via
restricted benefit (through EAP). Unlike other Cana-
dian provinces, the OPDP does not enforce a monthly
quantity limit. For example, in Manitoba, 4 triptans
are publicly funded and available with a quantity limit
of 12 per month, and in Quebec, 6 triptans are pub-
licly funded and available via GB.7 At the time of the
review, ergots were the only other class of drugs
funded under OPDP for the treatment of migraine
and were judged by the clinical experts as the appro-
priate comparator for analysis.
Of the 7 marketed triptans in Canada, 6 are avail-
able in generic formulation.7 For products available
as GB in Ontario, generic substitution for branded
products is required, and generic equivalents must
cost no more than 25% of the equivalent brand cost.
However in Ontario, as triptans are only available
under EAP, neither of these requirements is in place.
Moving triptans to GB appears to be an intuitive
strategy. However, there are concerns that such a
switch may lead to potential overuse of triptans,
which may be clinically harmful, and the possible
expansion of its indication to patients with cluster
headaches and other non-classic migraine headaches
(off-label use). Thus, the triptans drug class review
takes place in this context. After engagement with
relevant stakeholders, the following research ques-
tions were identified:
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1. What is the current evidence for the cost-
effectiveness of triptans (alone or in combination
with other drugs) for acute treatment of migraines
compared with: other triptans, acetaminophen,
antiemetics, acetylsalicylic acid, and ergots?
2. What is the economic impact of alternative reim-
bursement strategies for triptans (eg, restricted vs
more open access)?
WHAT IS REIMBURSEMENT-BASED
ECONOMICS?
Reimbursement-based economics is a novel,
pragmatic approach to pharmacoeconomics. Rather
than considering the traditional approach of compar-
ing 2 or more treatment options, reimbursement-
based economics focuses on comparing alternate
reimbursement strategies. Thus, the focus is on iden-
tifying the optimal reimbursement strategy.
Reimbursement-based economics involves: a
review of existing economic literature; a comprehen-
sive budget impact analysis assessing the impact dif-
ferent reimbursement strategies; and consideration
of the cost-effectiveness of such strategies, which will
include, where warranted, the development of tradi-
tional de novo pharmacoeconomic models focusing
on reimbursement strategies rather than treatment
options. The initial stage of the process is to deter-
mine the appropriate research questions with
respect to assessing cost-effectiveness and budget
impact – as illustrated above for the triptans analy-
sis. An essential component of this stage is engage-
ment with decision makers to determine feasible
alternative reimbursement strategies that are
operationalizible.
Review of Economic Literature.—Methods.—The
goal of the systematic review of economic evidence
is to identify existing relevant, well-conducted eco-
nomic evaluations to inform the strategies consid-
ered within the comprehensive budget impact
analysis, as well as assessing the need for de novo
economic modeling. A detailed review of the exist-
ing literature is conducted using a standardized
health economics search strategy.8 The review is
qualitative by nature as meta-analysis of cost-
effectiveness studies is neither feasible nor appropri-
ate given the multitude study designs and study
contexts. Focus is on identifying the relevance of the
current literature with respect to the current Cana-
dian context. Studies are assessed in terms of their
methodological rigor. It is important to note that
standard health economics checklists have relatively
limited discriminatory power with respect to assess-
ing study quality within a specific clinical area –
most studies will meet the base requirements of such
checklists but there may still be fundamental flaws
with the modeling approaches adopted. Thus, it is
necessary to identify the key areas of potential
concern particular to the disease of interest and
focus on the relevance of the methodology adopted
within studies to address these concerns. Studies
from other jurisdictions may have limited applicabil-
ity to the Canadian setting although consistency in
study findings can allow generalizability to findings
to other jurisdictions such as Canada.
The systematic review may further inform a deci-
sion to conduct a de novo economic modeling exer-
cise. Thus, the focus of the systematic review of
economic evidence is on the quality and the applica-
bility of the economic evidence in relation to the
reimbursement question.
Application to Triptans.—A systematic review
of published literature which compared the cost-
effectiveness of triptans to other triptans, acetamino-
phen, antiemetics, acetylsalicylic acid, and ergot
alkaloid-based medications (ergots) for the acute
treatment of migraines was conducted. The following
databases were searched using a standard health eco-
nomics search strategy augmented with terms related
to migraine and migraine therapy: Medline, Embase,
National Health Service Economic Evaluation Data-
base, and Tufts CEA registry (Table 1). As well, rel-
evant health technology assessment agency websites
were searched for grey literature. In addition, the ref-
erence lists of relevant studies were hand searched for
additional relevant literature.
The comprehensive search strategy identified 920
citations. Of these, 72 citations were identified for
full-text review. Citations were excluded for the
following reasons: not an economic analysis, not
migraine related, not relevant intervention, non-
English, not available, or not full text. Of the 72 eco-
nomic citations retrieved for detailed review, 21
Headache 3
Table 1.—Search Strategy for Review of Economic Evaluations of Triptans (Medline (Ovid) In Process and Other Non-Index
Citations 1946 to present (2013 November 11); Embase Classic & Embase 1947 to 2013 November 08)
1. exp Migraine Disorders/
2. (migrain* or migran*).tw.
3. (anti-migrain* or antimigrain* or anti-migran* or antimigran*).tw.
4. sick headache*.tw.
5. 1 or 2 or 3 or 4
6. exp Tryptamines/
7. (tryptamin* or tryptomin* or triptan* or indolylethylamine* or NSC 73938 or NSC73938).tw.
8. (“BRN 0125513” or CCRIS 8959 or EINECS 200-510-5 or Indol-3-ethylamine or UNII-422ZU9N5TV).tw.
9. Tryptamines.rn.
10. (almotriptan* or Almogran or Almotrex or Amignul or Axert or PNU 180638E or PNU-180638E or UNII-PJP312605E).tw.
11. almotriptan.rn.
12. (eletriptan* or Relpax or Relert or Relepax or “UK 116044” or “UK 116,044” or “UK-116044” or “UK-116,044” or
UNII-22QOO9B8KI).tw.
13. eletriptan.rn.
14. (frovatriptan* or Allegro or Frova or Frovelan or Migard or Miguard or SB 209509 or VML-251 or VML251).tw.
15. frovatriptan.rn.
16. (naratriptan* or Amerge or Colatan or Naragran or Naramig or UNII-QX3KXL1ZA2).tw.
17. naratriptan.rn.
18. (rizatriptan* or Risatriptan* or “L 705,126” or “L 705126” or “L-705,126” or “L-705126” or Maxalt or “MK 0462” or MK
462 or MK-0462 or MK-462 or rizalief or rizalt or rizaliv or UNII-51086HBW8G).tw.
19. rizatriptan.rn.
20. (sumatriptan* or Arcoiran or Alsuma or BRN 6930870 or Diletan or Dolmigral or GR 43175 or GR 43175X or GR-43175
or HSDB 7742 or Imigran* or Imiject or Imitrex or micranil or Migril or Novelian or Sumigrene or Suminat or Sumatran
or Sumatriptanum or Sumax or UNII-8R78F6L9VO or Zecuity).tw.
21. sumatriptan.rn.
22. (Zolmitriptan* or AscoTop or Flezol or Rapimelt or UNII-2FS66TH3YW or Zolmitriptan or Zomig or Zomig-ZMT or
Zomigon or Zomigoro).tw.
23. Zolmitriptan.rn.
24. (Treximet or Trexima).tw.
25. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26. 5 and 25
27. Economics/
28. exp “Costs and Cost Analysis”/
29. “Value of Life”/
30. exp Economics, Hospital/
31. Economics, Medical/
32. Economics, Nursing/
33. Economics, Pharmaceutical/
34. 27 or 28 or 29 or 30 or 31 or 32 or 33
35. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
36. (expenditure$ not energy).ti,ab.
37. (value adj1 money).ti,ab.
38. budget$.ti,ab.
39. 35 or 36 or 37 or 38
40. 34 or 39
41. 26 and 40
42. exp migraine/
43. (migrain* or migran*).tw.
44. (anti-migrain* or antimigrain* or anti-migran* or antimigran*).tw.
45. sick headache*.tw.
46. 42 or 43 or 44 or 45
47. tryptamine derivative/
48. triptan derivative/
49. (tryptamin* or tryptomin* or triptan* or indolylethylamine* or NSC 73938 or NSC73938).tw,tn.
50. (“BRN 0125513” or CCRIS 8959 or EINECS 200-510-5 or Indol-3-ethylamine or UNII-422ZU9N5TV).tw,tn.
51. 61-54-1.rn.
52. almotriptan/
53. (almotriptan* or Almogran or Almotrex or Amignul or Axert or PNU 180638E or PNU-180638E or
UNII-PJP312605E).tw,tn.
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publications addressed the objective of the review
and were selected for inclusion (Fig. 1).9-29
Common limitations relating to methodology
and applicability of the economic evaluations were
identified: limited generalizability to the Canadian
context, inappropriate outcomes (focus on costs per
successful treatment rather than incremental costs
per outcomes), analyses based on poor-quality effec-
tiveness and utility data, and lack of independence in
terms of study funding.
In terms of generalizability, only 3 of the
21 studies were Canadian.9,15,25 All of these
studies were published between 1995 and 2002
and therefore were based on dated information
and included drug costs prior to the availability
of generic formulations. Nine out of the 21
studies considered outcomes that would be consid-
ered inappropriate for making funding recom-
mendations within the context of economic
evaluation.11,13,16-19,21,23,26
Table 1.—Continued
54. 154323-57-6.rn.
55. eletriptan/
56. (eletriptan* or Relpax or Relert or Relepax or “UK 116044” or “UK 116,044” or “UK-116044” or “UK-116,044” or
UNII-22QOO9B8KI).tw,tn.
57. 143322-58-1.rn.
58. frovatriptan/
59. (frovatriptan* or Allegro or Frova or Frovelan or Migard or Miguard or SB 209509 or VML-251 or VML251).tw,tn.
60. 158747-02-5.rn.
61. naratriptan/
62. (naratriptan* or Amerge or Colatan or Naragran or Naramig or UNII-QX3KXL1ZA2).tw,tn.
63. 121679-13-8.rn.
64. rizatriptan/
65. (rizatriptan* or Risatriptan* or “L 705,126” or “L 705126” or “L-705,126” or “L-705126” or Maxalt or “MK 0462” or MK
462 or MK-0462 or MK-462 or rizalief or rizalt or rizaliv or UNII-51086HBW8G).tw,tn.
66. 144034-80-0.rn.
67. sumatriptan/
68. (sumatriptan* or Arcoiran or Alsuma or BRN 6930870 or Diletan or Dolmigral or GR 43175 or GR 43175X or GR-43175
or HSDB 7742 or Imigran* or Imiject or Imitrex or micranil or Migril or Novelian or Sumigrene or Suminat or Sumatran
or Sumatriptanum or Sumax or UNII-8R78F6L9VO or Zecuity).tw,tn.
69. 103628-46-2.rn.
70. zolmitriptan/
71. (Zolmitriptan* or AscoTop or Flezol or Rapimelt or UNII-2FS66TH3YW or Zolmitriptan or Zomig or Zomig-ZMT or
Zomigon or Zomigoro).tw,tn.
72. 139264-17-8.rn.
73. naproxen plus sumatriptan succinate/
74. (Treximet or Trexima).tw,tn.
75. 811794-26-0.rn.
76. 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68
or 69 or 70 or 71 or 72 or 73 or 74 or 75
77. 46 and 76
78. health economics/
79. exp economic evaluation/
80. exp “health care cost”/
81. exp pharmacoeconomics/
82. 78 or 79 or 80 or 81
83. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
84. (expenditure$ not energy).ti,ab.
85. (value adj2 money).ti,ab.
86. budget$.ti,ab.
87. 83 or 84 or 85 or 86
88. 82 or 87
89. 77 and 88
90. 41 or 89
91. remove duplicates from 90
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Eleven out of 21 studies17-19,21-25,27-29 used effective-
ness data,30 which had previously been considered of
low quality by the Canadian Agency for Drugs and
Technology in Health.31 None of the studies used
utility values that met Canadian guidelines for eco-
nomic evaluation.32 Only 8 of the 21 studies were
independent from industry funding.9,10,12,15,16,20,22,23
Two studies were assessed to be of suitable
quality for informing reimbursement strategies.10,12 A
report from the UK National Clinical Guideline
Centre suggested that for naïve patients, triptans were
more cost-effective than acetaminophen, ergots, and
non-steroidal anti-inflammatory drugs NSAIDs, and
that for experienced patients, the addition of NSAIDs
or acetaminophen to triptans dominated triptans
alone.10 The results from a Finnish Medicines Agency-
sponsored report imply that sumatriptan 100 mg
dominated all other triptans with the exception of
eletriptan 40 mg.12 Thus, the evidence from these 2
studies suggests that triptans are cost-effective com-
pared with ergots in the management of migraines.
Budget Impact Analysis.—Methods.—The focus of
the budget impact analysis is to identify the impact on
drug formulary expenditure of alternate reimburse-
ment strategies.This is done in 3 steps: forecast future
drug expenditure, identify candidate reimbursement
strategies, and assess budget impact of each candidate
reimbursement strategy.
The forecast of future expenditure involves the
use of historical drug utilization data to predict future
expenditure. Given the likely changing clinical envi-
ronment, typically future expenditure is forecasted
for no more than a 3-year period.
Analysis will typically use data from the OPDP
for each drug within the relevant class as well as,
where pertinent, drug expenditure for other alternate
drugs outside of the class of interest. Alternate model
specifications for predicting future expenditures are
examined: typically a linear model assuming a con-
stant increase by the same amount each year; an
exponential model assuming an exponential relation-
ship between expenditure and time; a power-based
Fig. 1.—Results of literature search.
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model assuming a flexible non-linear relationship
between time and expenditure; and a constant growth
model assuming a constant percentage increase in
expenditure for each quarter. Additional covariates
may be included within the model.These may include,
among others, the number of drugs within a specific
class to allow for any expansion of the expenditure,
changes to access within the drug formulary (eg, a
change in listing status), and the availability of newer
classes of drugs for the specific condition. In addition,
both absolute and Winter’s seasonal effects are exam-
ined for significance.
The choice of the most appropriate model is
based on statistical criteria – specifically the most suit-
able model is selected based on both the Bayesian
information criterion (BIC) and Akaike information
criterion (AIC). All analyses are conducted within
Microsoft Excel to facilitate the use of the models by
relevant decision makers within the OPDP.
At the onset of the reimbursement-based eco-
nomic analysis, it is necessary to identify potential
reimbursement strategies for the specific class under
review. Strategies are identified through involvement
of specific stakeholders: OPDP representatives and
clinical experts. Strategies could involve providing
either greater or more limited access through change
in listing status (eg, a movement from EAP or LU
would represent improved access, while movement to
EAP from GB would represent limited access).
Changes with respect to improved access may be
combined with strategies to reduce budgetary impact
through negotiated price reductions. Strategies may
also involve preferential listing of specific products –
such listings may be based on greater effectiveness for
1 product vs others within the same class, or may be
optimal due to differential costs of products within
the same class.
The final step within the budget impact analysis is
to estimate the impact on expenditure of the different
candidate reimbursement strategies. This involves
forecast of the change in volume of use for each drug
within the specific class. Ideally, such estimates will be
obtained by utilizing data from other jurisdictions
that have adopted similar reimbursement strategies
to the candidate strategies. When this is not possible,
the impact on volume can be assessed through
elicitation of clinical expert opinion regarding the
likely impact on prescribing habits of changes in
listing status.
Application to Triptans.—Within the context of
triptans, analysis used quarterly OPDP data on
the usage of triptans (almotriptan, naratriptan,
rizatriptan, sumatriptan, and zolmitriptan) from 2000
to 2012. Costs for each quarter were standardized
based on unit costs for each product from 2012 with
expenditure predicted for the next 3 years, 2013-2015.
All 4 forecasting models (linear, exponential power,
and constant growth) suggest an increase in triptan
expenditure over the next 3 years (Fig. 2). The BIC
(range 3633 to 3645) and AIC (range 3629 to 3638)
were similar across all models. Thus, the most simple
model (linear model) was adopted for assessing
the impact of alternate reimbursement strategies.
Without any change to the current reimbursement of
triptans, it is expected that triptan expenditure would
be approximately $1.75 million in 2014 (status quo)
(Table 2).
Given the different reimbursement policies
adopted across Canada, availability of generic
triptans and possibility of medication overuse for
headache, the following alternative approaches to
reimbursement were considered: changing listing
status (from EAP to GB or LU), enforcing generic
pricing restrains and/or generic substitution within
EAP, and incorporating monthly quantity limits (6,
12, and 18). A total of 20 reimbursement strategies
were identified during the scoping assessment along
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Fig. 2.—Forecast of triptan expenditure.
Source: Ontario Public Drug Programs claims data 2000-2012.
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with further consultation with the OPDP (Table 1).
For EAP scenarios without quantity limits, the unit
cost of triptans were changed to allow for generic
pricing and applied to the forecasted volume of
triptan use. For EAP scenarios with quantity limits,
the appropriate unit costs were applied to a reduced
volume based on the proportion of prescribed units
which would fall under the various limits. To estimate
the volume of use under less restrictive listing (GB/
LU) in Ontario, the volume of triptan use in any given
year for Ontario was multiplied by the ratio of the use
of triptans by beneficiary for other regions (in this
case Alberta/Manitoba) where less restrictive listing
is available. The costs of EAP were included in the
analysis based on the average cost of processing 1
application. For GB/LU with quantity limits, the same
adjustment as for EAP was then applied. For all
GB/LU strategies, the generic costs for triptans were
applied to the forecasted volume of triptan use.
A policy that requires generics to be priced at
25% of average branded cost may reduce expendi-
ture by 16% (EAP1) (Table 1). Combining reduced
generic costs with the requirement of replacement of
brand name agents with their generic formulation,
when available (EAP2), may reduce expenditure by
69% (Table 1). A similar policy, but with the addition
Table 2.—List of Potential Reimbursement Strategies and Their Predicted Budget Impact
Strategy Reimbursement Strategy 2014 Expected Cost† Impact‡
Status Quo No change to current reimbursement of triptans $1,752,377 –
EAP1 EAP with generic pricing $1,467,247 ↓ of 16%
EAP2 EAP with generic pricing and substitution, if available $550,268 ↓ of 69%
EAP3 EAP for generic products only $537,515 ↓ of 69%
EAP4 EAP 1 with quantity limit of 6 per month $744,842 ↓ of 57%
EAP5 EAP 2 with quantity limit of 6 per month $277,003 ↓ of 84%
EAP6 EAP 3 with quantity limit of 6 per month $271,781 ↓ of 84%
EAP7 EAP 1 with quantity limit of 12 per month $1,073,446 ↓ of 39%
EAP8 EAP 2 with quantity limit of 12 per month $398,617 ↓ of 77%
EAP9 EAP 3 with quantity limit of 12 per month $390,668 ↓ of 78%
EAP10 EAP 1 with quantity limit of 18 per month $1,308,618 ↓ of 25%
EAP11 EAP 2 with quantity limit of 18 per month $490,977 ↓ of 72%
EAP12 EAP 3 with quantity limit of 18 per month $479,870 ↓ of 73%
LU1 LU listing with generic pricing and substitution, if available $5,211,634 ↑ of 197%
LU2 LU listing for generic products only $5,088,066 ↑ of 190%
LU3 LU1 with quantity limit of 6 per month $4,052,143 ↑ of 131%
LU4 LU2 with quantity limit of 6 per month $3,960,532 ↑ of 126%
LU5 LU1 with quantity limit of 12 per month $4,904,750 ↑ of 180%
LU6 LU2 with quantity limit of 12 per month $4,790,905 ↑ of 173%
LU7 LU1 with quantity limit of 18 per month $5,071,950 ↑ of 189%
LU8 LU2 with quantity limit of 18 per month $4,953,481 ↑ of 183%
GB1 GB listing with generic pricing and substitution, if available $7,050,685 ↑ of 302%
GB2 GB listing for generic products only $6,883,513 ↑ of 293%
GB3 GB1 with quantity limit of 6 per month $4,189,249 ↑ of 139%
GB4 GB2 with quantity limit of 6 per month $4,100,941 ↑ of 134%
GB5 GB1 with quantity limit of 12 per month $5,619,145 ↑ of 221%
GB6 GB2 with quantity limit of 12 per month $5,497,328 ↑ of 214%
GB7 GB1 with quantity limit of 18 per month $6,251,231 ↑ of 257%
GB8 GB2 with quantity limit of 18 per month $6,113,241 ↑ of 249%
†Based on the linear model; results reported in 2014 Canadian dollars.
‡% change vs status quo.
GB strategies based on current prescribing practice in Alberta, where triptans are available similar to GB for eligible patients aged
18-64 years.
LU strategies based on current prescribing practice in Manitoba, where triptans are available similar to LU for eligible patients
aged 18-64 years.
EAP = Exceptional Access Program; GB = general benefit; LU = limited use.
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of a quantity limit of 12 per patient per month
(EAP8), may lead to a greater reduction in costs
(77%) (Table 1).
Coverage of triptans through GB without quan-
tity limit is expected to lead to an increase in triptan
expenditure by 302% (GB/LU1), while coverage of
triptans through LU with quantity limit of 12 per
month (GB/LU5), is forecasted to lead to an increase
of 221% (Table 1).
Consideration of Cost-Effectiveness.—Methods.
—The third stage is to consider the cost-effectiveness
of alternate reimbursement strategies. Where there is
sufficient evidence from existing literature, this can
be conducted based on the literature review in step 1.
In some cases, de novo economic evaluations are war-
ranted. In such instances, an economic model adher-
ing to current standards in the conduct of economic
evaluation will be developed.32 The focus of the de
novo economic evaluation would be to demonstrate
the relative value for money of alternate reimburse-
ment strategies rather than individual therapies – the
typical approach of economic evaluation. The first
step of this approach will be to estimate the asso-
ciated costs and outcomes for each potential
treatment. Following this, the likely use of each inter-
vention under each reimbursement strategy will be
estimated based on similar approaches adopted
within the budget impact analysis. Finally, the costs
and outcomes of each reimbursement strategy are
estimated by weighting the costs and outcomes for
each therapy by their expected utilization. From this,
the costs and outcomes of each strategy are esti-
mated and their relative cost-effectiveness can be
estimated using standard methodology. Thus, the goal
of this stage is to support the findings from the
budget impact analysis, identifying reimbursement
strategies that may be cost-effective and ruling out
strategies which are not.
Application to Triptans.—Based on the nature of
the research question, the results of the companion
clinical systematic review,33 and the consistent cost of
triptans (with the availability of many in generic for-
mulations), stakeholders concluded that there was no
requirement for a traditional economic evaluation to
assess the value for money for each of the candidate
treatments or reimbursement strategies. Specifically,
stakeholders argued that there was adequate evi-
dence to suggest that triptans are effective when
given to migraine patients, and cost-effective, espe-
cially given the availability of generic formulations.
DISCUSSION
Reimbursement-based economics is a novel
approach to pharmacoeconomics. Traditional eco-
nomic evaluation focuses on the economic attractive-
ness of specific therapies. Studies are conducted when
new technologies become available and funding is
requested – hence, the high proportion of existing
studies which are directly sponsored by industry.
Within reimbursement-based economics, the focus is
explicitly on the decision problem facing decision
makers with respect to the desire for formulary mod-
ernization and the related need to review the listing
status of drugs within specific classes or specific dis-
eases. The reimbursement-based economic approach
developed within the ODPRN involves a systematic
review of economic literature, comprehensive budget
impact analysis, and when warranted, a de novo eco-
nomic evaluation. The objective is to identify the
optimal reimbursement strategy for available drug
products.
Given the challenging fiscal situation and the
budgeted growth in OPDP expenditure for the next
few years, reimbursement-based economics has the
potential to be a valuable approach in helping
develop cost-effective and efficient use of the scarce
resources available for public drug funding. This
potential is highlighted through reference to a recent
application of reimbursement-based economics in the
context of triptans in the treatment of migraine.
Within the ODPRN analysis of triptans, the
evidence suggests that the use of triptans is cost-
effective if restricted to migraineurs, especially given
the availability of generic equivalents. Reimburse-
ment of triptans through a less restrictive listing (GB
or LU) would lead to a substantially wider use of
triptans at an increased expenditure. The findings
from the reimbursement-based economic analysis
were then considered in combination with findings
related to accessibility, effectiveness, and safety
derived from the other components of the class
review.33,34 From this, 2 reimbursement options for
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triptans were considered as potential funding alterna-
tives for OPDP and presented to the Ministry for
consideration.
There are limitations to the reimbursement-
based approach detailed. The limited time to conduct
the research (20 weeks from identification of research
questions to final report) precludes the conduct of
any primary research. Furthermore, the likely impact
of alternate reimbursement strategies cannot be
directly estimated empirically. Pilot studies to assess
changes in reimbursement status are neither feasible
nor desirable given the timely nature of the decisions
to be made. At best, inferences from other jurisdic-
tions can be drawn although in certain circumstances
analysis will be reliant on expert opinion relating to
likely changes in prescribing status.
A limitation of the example provided is the
limited evidence on the cost-effectiveness of triptans
in the current Canadian context. Ideally in situations
where the evidence base may be considered limited,
further studies may be commissioned. However, it
should be noted that the analysis relates to an actual
process of formulary modernization where the pro-
duction for research is highly time sensitive. In this
context, decision makers have identified a decision
problem and a willingness to address this through
changes in formulary listing. Decision makers consid-
ered the evidence available with respect to the cost-
effectiveness, effectiveness, and budget impact of the
alternate reimbursement strategies, and felt that
although limited, there was sufficient evidence to
make conclusions regarding the cost-effectiveness of
triptans. Thus, in the first application of the ODPRN
process, there was no requirement for de novo eco-
nomic modeling. Economics by its nature is a decision
science and research must be pertinent to real-world
decision making.Although the evidence base may not
be strong, identifying what evidence is available is still
a vital component of ensuring that the decisions that
will be made are as ideal as possible. Thus, the
reimbursement-based approach detailed is inherently
related to the decision-making process.
In this article, we have detailed the
reimbursement-based approach. It is a novel applica-
tion of pharmacoeconomics aiming to help facilitate
decisions relating to formulary modernization. The
conduct of this research in conjunction with other
qualitative and quantitative analyses is unique within
the health services literature and should ensure that
changes to formulary listing status in Ontario should
be evidence based.
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